ArticleJournal of diabetes investigation2025
Research on the characteristics of gut microbiota in overweight patients with early-onset type 2 diabetes mellitus.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut Microbiota in Metabolic Syndrome: Differences in Microbial Signatures and Clinical Profiles.Medicina (Kaunas, Lithuania) · 2026Review
- Association between body composition and dyslipidemia in middle-aged and elderly ethnic minorities in Guangxi.Scientific reports · 2026Article
- Perinatal antibiotics in a db/db mouse model impact obesity and hyperglycemia in a microbiome-dependent manner.Frontiers in microbiomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEarly-onset type 2 diabetes mellitus (EOD), defined as a metabolic disorder diagnosed before the age of 40, with higher risks of complications, vascular events, and mortality, poses a significant threat to public health. Its prevalence has risen markedly in overweight populations in recent years, yet the underlying mechanisms remain elusive. Emerging evidence highlights a close association between gut microbiota (GM) and metabolic disorders, suggesting that modulating gut microbial dysbiosis may serve as a potential strategy for preventing and managing overweight EOD.
methodsIn this study, we enrolled 30 overweight EOD patients and 30 healthy controls, analyzing their GM profiles and correlations using physicochemical clinical parameters and fecal metabolites.
resultsThe results demonstrated significant differences in GM composition between overweight EOD patients and healthy controls. EOD patients exhibited increased the ratio of Firmicutes/Bacteroidetes at the phylum level. At the genus level, Bilophila, Serratia, Lachnospira, and Parabacteroides were enriched in EOD patients, while taxa, such as Faecalibacterium, Ruminococcaceae, and Clostridia_UCG-014, showed significant depletion. Correlation analyses revealed that Clostridia_UCG-014 abundance was negatively associated with body mass index (BMI) (P < 0.05), waist-to-height ratio (WHtR) (P < 0.05), fasting plasma glucose (FPG) (P < 0.05), low-density lipoprotein cholesterol (LDL-C) (P < 0.05), and triglycerides (TG) (P < 0.05), but positively correlated with high-density lipoprotein cholesterol (HDL-C) (P < 0.05). Conversely, Bilophila abundance displayed positive correlations with BMI (P < 0.05), WHtR (P < 0.05), FPG (P < 0.05), LDL-C (P < 0.05), and TG (P < 0.05). Meanwhile, biofilm formation (Escherichia coli), nitrogen metabolism, arginine and proline metabolism, beta-lactam resistance, drug metabolism (other enzymes), glycerolipid metabolism and sucrose metabolism showed decreases in overweight EOD patients, respectively (P < 0.05).
conclusionsThese results indicate that Bilophila and Clostridia_UCG-014 may serve as microbial biomarkers for the identification of obesity-related EOD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.